<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> is a common clinical problem </plain></SENT>
<SENT sid="1" pm="."><plain>If patients can undergo resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, long-term survival can be achieved </plain></SENT>
<SENT sid="2" pm="."><plain>Converting a patient from unresectable to resectable, however, remains a major challenge </plain></SENT>
<SENT sid="3" pm="."><plain>The majority of patients who undergo liver resection for colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> recur; therefore, adjuvant treatment following resection should be considered </plain></SENT>
<SENT sid="4" pm="."><plain>Emerging literature suggests that hepatic arterial infusion (HAI) can be combined with systemic chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Both therapies can be given at nearly full doses, thus improving resectability and outcomes for patients with colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>HAI plus systemic can also be a useful option for adjuvant treatment after hepatic resection </plain></SENT>
</text></document>